We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+16.88%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.03B
AUM Growth
-$287M
(-22%)
Cap. Flow
-$398M
Cap. Flow
% of AUM
-38.68%
Top 10 Holdings %
Top 10 Hldgs %
14.04%
Holding
1,478
New
335
Increased
269
Reduced
346
Closed
503
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$12.3M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$10.9M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$10.4M |
| 4 |
Tesla
TSLA
|
+$9.96M |
| 5 |
NVIDIA
NVDA
|
+$8.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.4M |
| 2 |
Broadcom
AVGO
|
+$9.33M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$8.68M |
| 4 |
DESP
Despegar.com
DESP
|
+$7.15M |
| 5 |
Oracle
ORCL
|
+$6.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.86% |
| 2 | Consumer Discretionary | 12.74% |
| 3 | Healthcare | 12.34% |
| 4 | Communication Services | 10.34% |
| 5 | Industrials | 8.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Cineverse
CNVS
$65.6M
| $62.1K | 0.01% |
13,000
| – | – |
|
|
INV
952
Innventure Inc
INV
$289M
| $61.2K | 0.01% |
+12,744
| New | +$60.8K |
|
|
TIXT
953
DELISTED
TELUS International
TIXT
| $58K | 0.01% |
+15,982
| New | +$45.4K |
|
954
Newell Brands
NWL
$2.56B
| $57.8K | 0.01% |
+10,711
| New | +$56.8K |
|
955
Relay Therapeutics
RLAY
$4.33B
| $57.4K | 0.01% |
16,600
-4,600
| -22% | -$13.7K |
|
|
ABX
956
Abacus Global Management
ABX
$913M
| $56.8K | 0.01% |
+11,054
| New | +$81.6K |
|
957
Expensify
EXFY
$245M
| $55.9K | 0.01% |
+21,600
| New | +$55.2K |
|
|
CTNM
958
Contineum Therapeutics
CTNM
$566M
| $55.3K | 0.01% |
+13,920
| New | +$60.5K |
|
|
HBI
959
DELISTED
Hanesbrands
HBI
| $50.5K | ﹤0.01% |
+11,031
| New | +$53.2K |
|
960
Krispy Kreme
DNUT
$577M
| $47.2K | ﹤0.01% |
+16,211
| New | +$56.6K |
|
|
NFGC
961
New Found Gold
NFGC
$641M
| $45.8K | ﹤0.01% |
32,235
-2,427
| -7% | -$3.13K |
|
962
AtaiBeckley Inc
ATAI
$2.68B
| $45.4K | ﹤0.01% |
20,745
-1,563
| -7% | -$2.8K |
|
963
Talkspace
TALK
$874M
| $42K | ﹤0.01% |
+15,100
| New | +$44.5K |
|
|
VTYX
964
DELISTED
Ventyx Biosciences
VTYX
| $33.6K | ﹤0.01% |
+15,700
| New | +$25.4K |
|
|
ALMS
965
Alumis Inc
ALMS
$3.52B
| $33K | ﹤0.01% |
11,007
+587
| +6% | +$2.77K |
|
966
Larimar Therapeutics
LRMR
$432M
| $31.4K | ﹤0.01% |
+10,867
| New | +$25.2K |
|
967
Smart Sand
SND
$194M
| $31K | ﹤0.01% |
15,400
+500
| +3% | +$1.01K |
|
|
HLVX
968
DELISTED
HilleVax
HLVX
| $26.7K | ﹤0.01% |
13,411
-8,689
| -39% | -$15.9K |
|
969
United States Antimony
UAMY
$1.02B
| $26.4K | ﹤0.01% |
12,100
-2,200
| -15% | -$6.23K |
|
970
Myomo
MYO
$56.2M
| $26.4K | ﹤0.01% |
+12,200
| New | +$44.2K |
|
971
Alto Neuroscience
ANRO
$1.11B
| $25.1K | ﹤0.01% |
11,401
-2,244
| -16% | -$5.34K |
|
972
Kaltura
KLTR
$267M
| $21.9K | ﹤0.01% |
+10,900
| New | +$22.6K |
|
|
SAFX
973
XCF Global Inc
SAFX
$158M
| $19.7K | ﹤0.01% |
+11,197
| New | +$69.4K |
|
974
Polestar Automotive Holding ADS Class C-1
PSNYW
$387M
| $2.38K | ﹤0.01% |
551
| – | – |
|
|
KPLTW
975
DELISTED
Katapult Holdings Warrant
KPLTW
| $229 | ﹤0.01% |
28,680
| – | – |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Prelude Capital Management held 1,478 positions worth $1.03B, down 22% from $1.32B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Prelude Capital Management withdrew a net $398M in Q2 2025, closing 503 positions and reducing 346 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Prelude Capital Management opened a new position in Alphabet (Google) Class C worth $11.7M.
- Prelude Capital Management's largest Q2 2025 buy was Alphabet (Google) Class C: 65,723 shares worth $11.7M.
- Prelude Capital Management added most to Meta Platforms (Facebook) in Q2 2025, an estimated $12.3M increase.
- Prelude Capital Management's biggest Q2 2025 reduction was Broadcom, cutting an estimated $9.33M.
- Prelude Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $10.4M.
- Prelude Capital Management's ten largest holdings make up 14% of its $1.03B portfolio in Q2 2025.
- Prelude Capital Management opened 335 new positions and closed 503 in Q2 2025.
- Prelude Capital Management's portfolio value fell 22% quarter-over-quarter to $1.03B.
Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.